PRESS-RELEASE ·Filed Oct 21, 2026
Press release · Earnings
Price Chart
Loading chart...
Executive Summary
BioCryst Pharmaceuticals, Inc. announced it will report its Q3 2026 results on November 4.
Key Facts
- BioCryst Pharmaceuticals, Inc. announced it will report its Q3 2026 results on November 4.
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3385876 |
14 reports for BCRX
67% Hit rate @ T+20 Went positive at some point 3 of 3 best @ T+20▲ +21.01%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Institutional Cluster | $8.09 | awaiting T+20 | — | $8.10 (+0.12%) |
Oct 21, 2026 6d ago | Press Release | $7.78 | awaiting T+20 | — | $8.10 (+4.11%) |
Aug 5, 2026 11w ago | 8-K | $9.07 $10.17 | ▲ +12.13% | ▲ +12.73% | $8.10 (−10.69%) |
Jun 29, 2026 17w ago | 8-K | $9.55 $9.34 | ▼ −2.20% | ▼ −1.92% | $8.10 (−15.18%) |
Jun 12, 2026 19w ago | 8-K | $9.06 $9.91 | ▲ +9.38% | ▲ +10.13% | $8.10 (−10.60%) |
Jun 12, 2026 19w ago | Press Release | $8.70 $10.45 | ▲ +20.11% | ▲ +18.34% | $8.10 (−6.90%) |
May 19, 2026 23w ago | Insider Cluster | $8.74 $8.99 | ▲ +2.86% | ▲ +2.12% | $8.10 (−7.32%) |
May 13, 2026 23w ago | 144 | $9.60 $8.50 | ▼ −11.46% | ▼ −10.85% | $8.10 (−15.62%) |
May 6, 2026 24w ago | 8-K | $8.83 $8.25 | ▼ −6.57% | ▼ −9.35% | $8.10 (−8.27%) |
May 4, 2026 25w ago | 8-K | $9.20 $8.57 | ▼ −6.85% | ▼ −12.49% | $8.10 (−11.96%) |
Showing 10 of 14
US Market Status
Market Closed — Opens in 8h 21m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers